Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Free Cash Flow (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Free Cash Flow data on record, last reported at -$65.2 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 96.27% year-over-year to -$65.2 million; the TTM value through Dec 2025 reached -$213.7 million, down 33.79%, while the annual FY2025 figure was -$213.7 million, 33.79% down from the prior year.
  • Free Cash Flow reached -$65.2 million in Q4 2025 per CLDX's latest filing, down from -$49.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$12.1 million in Q2 2021 and bottomed at -$65.2 million in Q4 2025.
  • Average Free Cash Flow over 5 years is -$32.5 million, with a median of -$29.4 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: skyrocketed 46.11% in 2023, then plummeted 191.81% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$14.9 million in 2021, then crashed by 47.86% to -$22.0 million in 2022, then tumbled by 50.93% to -$33.2 million in 2023, then fell by 0.1% to -$33.2 million in 2024, then plummeted by 96.27% to -$65.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$65.2 million in Q4 2025, -$49.0 million in Q3 2025, and -$44.8 million in Q2 2025.